In the market’s stunning recovery, some stocks are more to thank than others. Wall Street sees a handful of the best performers having more room to run. The S & P 500 notched an all-time high on Friday, the latest milestone in the equity comeback after President Donald Trump ‘s tariff policy sent markets into a tailspin. The Nasdaq Composite has surged with tech stocks leading the recovery, driving the index more than 15% higher since Trump first announced the levy plan on April 2, the day he dubbed “liberation day.” CNBC Pro screened for Nasdaq members with market caps of at least $5 billion that have led the market’s rebound. From there, we looked for names that have buy ratings from at least 65% of analysts and have average price targets implying upside of 15% or more. All of the stocks on this list are covered by at least 15 Wall Street analysts. Data is current as of midday Friday and is from FactSet. Here are the names that made the list: BridgeBio Pharma has surged more than 30% since April 2, bringing its year-to-date gain above 61%. Earlier this month, the U.S. Food and Drug Administration granted a BridgeBio subsidiary orphan drug status for infigratinib, a treatment for a form of dwarfism known as hypochondroplasia. Four out of five analysts have buy ratings on the stock, according to FactSet. The typical price target suggests shares can jump more than 34%. BBIO 3M mountain BridgeBio, 3-month chart AppLovin is one of the better-known names of the list. Shares have rallied more than 19% since April and are now up more than 6% in 2025. A chunk of that gain came after the company last month reported better earnings than analysts expected. About 2 out of every 3 analysts have buy ratings on the stock. Wall Street sees much more upside ahead, with an average price target implying the stock can soar more than 41%.
